Comparison of Early T-Cell Precursor and Non-ETP Subtypes Among 122 Chinese Adults With Acute Lymphoblastic Leukemia

Yi Zhang,Jie-Jing Qian,Yi-Le Zhou,Xin Huang,Jian-Hu Li,Xue-Ying Li,Chen-Ying Li,Huan-Ping Wang,Yin-Jun Lou,Hai-Tao Meng,Wen-Juan Yu,Hong-Yan Tong,Jie Jin,Hong-Hu Zhu
DOI: https://doi.org/10.3389/fonc.2020.01423
IF: 4.7
2020-08-21
Frontiers in Oncology
Abstract:<span><strong>Background:</strong> Adult T-cell acute lymphoblastic leukemia (T-ALL) is a rare hematological malignancy and significantly linked to poor outcomes. Early T-cell precursor (ETP) leukemia is a unique subtype of T-ALL. The aim of this study is to compare the differences between ETP and non-ETP ALLs in China.<strong>Methods:</strong> We retrospectively analyzed the records of 122 adult T-ALL patients diagnosed and treated at our center between January 2014 and June 2019. All the patients enrolled were categorized into ETP and non-ETP ALL by immunophenotype, and further statistical analyses about clinical data and prognostic factors were performed.<strong>Results:</strong> Among the 122 cases, the male-to-female ratio was 2.8:1, and the median age is 29 (range, 16–82) years. Except for 10 patients with insufficient immunophenotyping results, 47.3% (53/112) are ETP and 52.7% (59/112) are non-ETP. Compared with non-ETP patients, ETP-ALL patients had lower white blood cell counts and lactate dehydrogenase levels, while they were older and had higher platelet counts and fibrinogen levels (all <i>p</i> &lt; 0.05). Complete remission (CR) was achieved in 68.0% (83/122) of patients, 64.2 and 76.3% in ETP and non-ETP, respectively (<i>p</i> = 0.160). In total, 44.6% (37/83) of patients relapsed. Allogeneic stem cell transplantation (allo-SCT) was successfully performed in 36.1% (44/122) of patients, of which 79.5% (35/44) were in CR1. With a median follow-up of 9.1 (range, 0.5–70.3) months, the estimated 2-year overall survival (OS) and relapse-free survival (RFS) rates for the cohort were 38.0 ± 5.1 and 39.1 ± 6.3%, respectively. In the ETP group, the 2-year OS rate was 40.7 ± 8.2% and the RFS rate was 47.2 ± 10.7%, while in the non-ETP group, the 2-year OS rate was 37.9 ± 7.0% and the RFS rate was 39.2 ± 8.3% (both <i>p</i> &gt; 0.05). In the landmark analysis of CR1 patients who had a survival of more than 6 months, the allo-SCT group had significantly better survival outcomes than the chemotherapy group, and the 2-year OS rates and RFS rates were 80.1 ± 7.3 vs. 28.4 ± 8.4% and 68.9 ± 8.8 vs. 12.8 ± 7.2%, respectively (both <i>p</i> &lt; 0.0001). A multivariate analysis suggests that allo-SCT acts as an independent prognostic factor for both OS and RFS.<strong>Conclusions:</strong> Our results revealed that ETP accounted for a high proportion of T-ALL in Chinese. There are no CR rates and prognosis differences between ETP and non-ETP. Allo-SCT in CR1 can significantly improve patients' survival.</span>
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the differences between the early T - cell precursor (ETP) subtype and the non - ETP subtype in adult acute T - lymphoblastic leukemia (T - ALL) in China. Specifically, the study aims to compare the differences between these two subtypes in terms of clinical features, treatment responses and prognoses, and to evaluate the impact of allogeneic hematopoietic stem cell transplantation (allo - SCT) on the survival of these patients. Through this study, the authors hope to provide a clearer understanding of the characteristics and prognoses of adult T - ALL in China, especially for the special group of the ETP subtype. The research background indicates that adult T - ALL is a rare hematological malignancy with a poor prognosis, and the ETP subtype is a unique subtype of T - ALL. Due to the lack of complete data on adult T - ALL in China and insufficient understanding of the differences between ETP and non - ETP, the goal of this study is to compare the characteristic and prognostic differences between these two subtypes, in order to provide a reference for the clinical diagnosis and treatment of adult T - ALL in China. By retrospectively analyzing the records of 122 adult T - ALL patients diagnosed and treated in a center in China, the researchers divided the patients into ETP and non - ETP groups according to the immunophenotype and carried out detailed statistical analysis. The research results revealed a high proportion of ETP in adult T - ALL patients in China, and found that there were significant differences between ETP and non - ETP in some clinical indicators, but there were no significant differences between the two groups in terms of complete remission rate (CR) and long - term survival. In addition, the study also emphasized that allo - SCT at the time of the first complete remission (CR1) can significantly improve the survival status of patients.